Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

BACKGROUND: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC). OBJECTIVE: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARP...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicoletto, Maria Ornella, Baldoni, Alessandra, Cavallin, Francesco, Grego, Andrea, Falci, Cristina, Nardin, Margherita, Mammano, Enzo, Lai, Eleonora, Torri, Valter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288417/
https://www.ncbi.nlm.nih.gov/pubmed/37360767
http://dx.doi.org/10.1177/17588359231173181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288417/
https://www.ncbi.nlm.nih.gov/pubmed/37360767
http://dx.doi.org/10.1177/17588359231173181

Ejemplares similares